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ABSTRACT. Evolution of multi-drug resistance strains of Mycobacterium tuberculosis 
(MTB) has in the past caused severe epidemics of tuberculosis across the globe thereby it 
raises a question on the potency or efficacy of the current scaffolds of drugs targeting MTB. 
Therefore, there an urgency to identify novel antimycobacterial compounds targeting 
proteins important for the viability of Multi-Drug-Resistant Tuberculosis (MDR-TB) strains. 
In this regard, Mtb LprG (Rv1411c) a lipoprotein involved in the elusion of cell-mediated 
immune response within infected host macrophages, is an important target for screening 
antimycobacterial compounds against Mtb. In the current study, a workflow comprising of 
virtual screening of ligand using USRCAT (Ultra Shape Recognition) and molecular 
docking protocols were employed to identify novel antituberculosis compounds. Based on 
USRCAT and docking studies XPX an analog of triacylated glycolipid was screened as a 
promising lead molecule that shows higher specificity and binding affinity for Mtb LprG 
protein. Further, in vitro experimentations are required to testify the role of XPX as an 
anti-TB drug for the treatment of MDT-TB.   
Keywords: Multi-drug Resistant Tuberculosis; Toll-like receptor 2 (TLR2); antagonist; 
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1. Introduction. Tuberculosis (TB) a highly infectious disease which continues to cause an alarming toll on a 
human being worldwide. In 2012, there were around 8.6 million TB cases were reported and the casualty 1.3 
million approximately. Among these deaths, there were an estimated 170000 from Multidrug-Resistance 
Tuberculosis (MDR-TB), a relatively high total compared with 45000 cases of MDR-TB [1]. In this context, 
research effort to identify novel target specific antituberculosis compounds against diverse strains of M. 
tuberculosis is an important step in combating the growing menace of MDR strains of Mycobacterium 
tuberculosis across the globe [2].  
LprG (Rv1411c) lipoprotein is involved in the TLR2 depended on evasion of immune responses 
with host macrophages. The LprG protein acts as an agonist for TLR2 receptor protein and the efficacy of the 
TLR2-LprG interaction is enhanced by the formation of an intermediate complex between the LprG and 
triacylated glycolipids. The triacylated glycolipid binds precisely at the hydrophobic residues lining the cavity 
of H37Rv-LprG protein. The finding of a triacylated glycolipid in the hydrophobic pocket of LprG protein has 
vital effects on the role of LprG protein in the survival, persistence, and physiology of MTB in the host 
macrophages [3]. The encoding of p55 (Rv1410c) and LprG (Rv1411c) in a particular operon are significant 
for virulence [4-6]. Prolonged exposure of more than 16 h of human macrophages to H37Rv-LprG lipoprotein 
(TLR2 receptor acylated agonist) results in visible inhibition of MHC-II Ag processing. Furthermore, MHC-II 
Ag processing inhibition by H37Rv-LprG lipoproteins may permit survival of MTB within infected 
1
 macrophages, by evading the innate immune reaction of the host [7].  
Considering the critical role played by triacylated glycolipids in evading immune responses by 
enhancing the agonist activity of LprG protein, therefore screening antagonist molecules that bind specifically 
to the hydrophobic binding pocket of LprG lipoprotein. This antagonist-LprG protein interaction will cause 
inhibition of cell wall biogenesis, and TLR 2 agonist-mediated immune evasion of the host in tuberculosis 
infection.  
Recently, conducted an analysis of the usage of computational techniques towards the discovery of 
drugs for TB, shows that the action of HTS against post-genomic antibacterial targets mostly has not been 
satisfactory. Moreover, the restricted chemical diversity of the screened collection and low druggability of 
antituberculosis targets also lead to poor efficiency of HTS [8-9]. Finally, these computational prototypes are 
used with negligible incorporation into the typical workflow of drug discovery for TB [10]. Moreover, 
compound classification methods and machine learning have been rarely put into practice. These methods are 
particularly operative for the computer-generated collection of libraries [11-12]. In spite of the fact that there 
is a crucial need for new alternative medicines [13-14], there has hardly been any new breakthrough in past 40 
years except for the newly accepted bedaquiline for multidrug-resistant TB [15] However, there are other 
upcoming medicines undergoing medical trials. 
In this regard, ligand-based virtual screening protocol USRCAT software [16-19] was used to 
identify ligand similar in structure to triacylated glycolipid (Ac1PIM2) and the ligand screened will be 
examined for their specificity and affinity for the hydrophobic ligand-binding domain (LBD) of LprG protein 
using AutoDock Vina 1.1.2 [20]. The crystal structure of H37RV-LprG protein [3] was used for performing 
the protein-ligand docking protocol. Finally, the highly specific antagonist ligands were obtained through 
computationally demanding docking scoring function analysis.  
The present work is a step forward by our group to comprehend the computational approach 
developed to increase the efficiency of screening novel antagonists, binding specifically to a target site in a 
given protein. This project will help us to explore unconquered horizon in screening novel antituberculosis 
drugs binding specifically to Mtb LprG, from the vast molecular database available. 
 The paper is organized as follows. Section 2 is devoted methods used for screening antagonists of 
LprG protein. The results and discussion of the screening process are represented in Section 3. Section 4 
highlight the concluding remarks of the present research work. 
 
2. Methodology: In this section, we screened analogs from CREDO dataset using Ultra-Fast Shape 
Recognition (USRCAT) software and performed docking and toxicity studies to screen drug-like antagonist 
analog molecule. 
 Screening database. We will use the CREDO dataset available online at 
http://www-cryst.bioc.cam.ac.uk/credo for screening structural interaction fingerprints of protein and 
ligand molecule similar to that of LprG protein and triacylated glycolipid (PIM2) complex. 
 Shape similarity screen. USRCAT software was used for the shape similarity screening using the 
co-crystallized Mycobacterium tuberculosis LprG ligand (LprG-PIM2) as the search template 
(Ac1PIM2 from PDB code 3MHA) [3]. The similarity threshold of USRCAT was set to 0.9, in just 
90 seconds using a quad-processing core of a laptop computer (including both reading descriptors 
from file and screening time). InstantJchem software was used to retrieve the 3D conformers 
corresponding to USR hits from the screening database. 
 Ligand preparation. The structures downloaded from InstantJchem software were in .sdf format. 
OpenBabel (http://openbabel.org/wiki/Main_Page) software was used to convert the .sdf files to 
.mol2 format since autodock vina docking tool requires structural files in .mol2 format for 
performing molecular docking calculations. Ready to use dock prep structures of analogs of 
triacylated glycolipid were prepared using Chimera 1.10. 
 Ligand Binding Site Preparation. The LprG protein in complex with acylated glycolipid was 
downloaded in .pdb format from RCSB PDB (PDB ID 3MHA). The binding region of the bounded 
agonist was defined as the binding site for virtual screening. The bounded agonist was defined as the 
center of the binding domain and the size of the binding position was set to a default value of 8 Å. 
 Docking Virtual Screening Calculation. The resulting ligand obtained through USRCAT were 
docked will be docked into the hydrophobic pocket of the crystal structure of Mtb LprG lipoprotein 
(PDB CODE 3MHA) using AutoDock Vina 1.1.2. The crystal structure has a resolution of 2.0 Å. 
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The molecular docking procedure was preset to rigid conditions and the docking grid was set to 
encompass the dimer interface of LprG-Ligand binding domain (LBD). The parameter 
exhaustiveness was preset to twenty while the remaining parameters were set to default standard 
values. All calculations were performed by the Intel Core i7 processor and Ubuntu 12.04 Operating 
System with a RAM of 8 GB. The top-ranking chemical compounds were ordered based on the 
values of their binding affinity for LprG protein and the geometry and docking poses were examined. 
AutoDock Vina was used to generating docking poses, which were later loaded directly to Chimera. 
Chimera was employed to generate the pictures of the protein-ligands complex. 
 Docking energy analysis. A high performing program, DSX (DrugScore eXtented) [21], was used 
to check the affinity of the screened antagonist molecule with LprG protein. The molecule, which 
has higher affinity, will have higher negative value.  
 Toxicity Analysis. All the analogs of acylated glycolipid were subjected to toxicity prediction 
through ACD/Labs for all toxicity profiles like mutagenicity, carcinogenicity, irritant effects and 
reproductive effect. Toxicity analysis was done to know about the probable undesired effects of the 
drug in the body. 
 PAIN-Remover Assay. The structural filters will be used to flag hits that might demonstrate a 
nonspecific activity these compounds were termed PAINS for Pan-Assay Interference compound 
[22]. We will use the most up-to-date version. It is noteworthy that the compound used for filtering 
may not include some of the useful molecules for further consideration. Indeed, it is enough for a 
member of a chemical series to be found promiscuous for all other members to be also considered 
promiscuous. 
 
3. Results and Discussion. In this section, we describe the results of the ligand-based virtual screening, 
toxicity, and nonspecificity studies of the screened ligands. 
Identification of potential lead antagonist molecules using shape-based screening (USRCAT), 
 Molecular Docking and DSX analysis. To identify potential lead compounds that display LprG 
antagonistic properties, CREDO database for atom pair fingerprints with Tanimoto similarity and trigram 
(LINGO) similarity were used to screen ligand similar to triacylated glycolipids (Ac1PIM2). Based upon 
atom pair fingerprint, trigram (LINGO) similarity and Lipinski criteria [23], we could screen four chemical 
component similar to triacylated glycolipid as shown in Table 1 and 2, respectively.  
 
Table 1. Top-ranked similar chemical components using trigram (LINGO) similarity 
Sl. 
No
. 
Similarity HET-
ID 
MW Heavy 
Atoms 
Ring 
Systems 
Aromatic 
Ring 
Systems 
Lipinski 
HDB 
Lipinski 
HBA 
tPSA XLogP 
1 0.679 DSU 496 34 2 0 12 6 184.
6 
1.43 
d2
. 
0.615 FUG 459 33 2 0 7 1 108.
4 
3.92 
 
Table 2. Top-ranked similar chemical components using trigram (LINGO) similarity 
Sl. 
No
. 
Similarity HET-
ID 
MW Heavy 
Atoms 
Ring 
Systems 
Aromatic 
Ring 
Systems 
Lipinski 
HDB 
Lipinski 
HBA 
tPSA XLogP 
1 0.762 XPX 1134 77 3 0 23 11 370.6 6.4 
2. 0.602 UDG 1016 68 3 1 23 8 358.0 3.77 
 
The chemical component screened through USR for their specificity and affinity for the 
hydrophobic ligand-binding domain of LprG protein using AutoDock Vina. Based upon the predicted binding 
free energies (ΔGvina) and DSX value, we observed that XPX 
([(2R)-2,3-di(hexadecanoyloxy)propyl][(2S,3S,5S,6R)-3,4,5-trihydroxy-2,6-bis[[(2R,3S,4S,5R,6S)-3,4,5-trih
ydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy]cyclohexyl] phosphate]) showed minimum binding free 
energy value and larger negative score as compared to other ligands as represented in Table 3.  
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Table 3. Docking energy and DSX analysis of the ligand-LprG protein complex 
 
Sl. No Ligand Free Binding Energy DSX Score 
1. DSU -8.08e+006 -120.35 
2. FUG -8.82e+006 -121 
3. XPX -8.98e+006 -126 
4. UDG -8.76e+006 -107.35 
 PIM2 (Positive control) -9.08e+006 -127 
 
The output binding conformation of the ligand XPX in the hydrophobic ligand binding pocket of LprG 
protein was visualized using Chimera software (Figure 1 (a-b)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Triacylated glycolipid (PIM2) was used as a positive control for the above study. The predicted 
binding free energy and its corresponding DSX value of XPX were almost identical to that of the PIM2. 
Hence, we propose from our current understanding that the compound XPX can be a potential inhibitor of the 
agonist activity of the LprG protein that leads to TLR2 mediated immune evasion within host macrophages, 
causing virulence and latency in tuberculosis infection. 
Toxicity studies. The screened ligands were further screened for their toxic properties. Table 4 shows the 
results of ACD/I-Lab toxicity analysis of the drug-like analogs of acylated glycolipid. It was observed that 
XPX an analog of triacylated glycolipid was identified as a non-toxic chemical entity when compared to DSU, 
FUG, and UDG. Both DSU and UDG were predicted to be carcinogenic agents since the probability of 
positive AMES test for NII and MNY were 0.95 and 0.91, respectively. AMES test is formally a biological 
assay to evaluate the potential of chemical compounds to cause mutation in DNA [24]. The chemical analog 
FUG, on the other hand, was predicted to be an endocrine disruptor since OX5 was predicted to be a binder of 
Estrogen Receptor alpha (ERα). ERα is a type of estrogen receptor, which get activated by the sex hormone 
estrogen [25-27]. The probability of toxic effect of DSU, FUG and MNY on the gastrointestinal system, lungs, 
blood, kidney, and blood were comparably higher than XPX.  
Figure-1 (a): Pictorial representation of the 
hydrophobicity surface view of the docked 
LprG and XPX complex. The hydrophobic 
region are represented by orange color, the 
hydrophilic surface by blue and neutral surface 
by white color  
Figure 1-(b): Pictorial representation of the 
secondary structure of the docked LprG 
(protein) and XPX (Ligand) complex.  
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It is noteworthy to state that XPX chemical analogs of triacylated glycolipid which is an agonist 
molecule of triacylated glycolipid can prove to be the best-fit antagonist of LprG protein.  
 
Table 4. ACD/I-Lab toxicity properties analysis of the drug-like analogs of acylated glycolipids 
 
Chemical 
Molecule 
 
AMES 
Test 
[Carcinog
enic] 
 
Endocrin
e 
disruptio
n 
 
Genoto
xicity 
Hazard 
 
Probability of effect on 
 
Blo
od 
 
Cardiovasc
ular 
system 
 
Gastrointes
tinal 
System 
 
Kidn
ey 
 
Liv
er 
 
Lun
gs 
DSU Positive Negative  Positiv
e 
0.65 0.30 0.89 0.44 0.3
4 
0.70 
FUG Negative  Positive  Negativ
e  
0.66 0.73 0.75 0.24 0.1
5 
0.6 
XPX Negative Negative  Negativ
e 
0.21 0.23 0.46 0.29 0.1
8 
0.52 
UDG Positive Positive  Negativ
e  
0.39 0.75 0.85 0.46 0.1 0.36 
 
PAIN-Remover Assay. PAINS-Remover is designed and constructed to remove the Pan Assay Interference 
Compounds (PAINS) from screening libraries and for their exclusion in bioassays. In this study, we found 
that XPX analog of triacylated glycolipid passed the bell and Holloway filter. 
 
4. Conclusion. Discovering antagonists to regulate the function of LprG protein as an agonist of TLR2 
mediated immune evasion in tuberculosis infection in humans will offer several avenues in the field drug 
discovery against tuberculosis. In this context, we were successful in identifying four drug-like compounds 
using ligand-based virtual screening and docking protocol. All of these compounds, DSU, FUG, XPX and 
DUG have a similar affinity for LprG protein, as established by the minimum free binding energy values. 
Furthermore, DSX based binding energy analysis showed that all the four screened compounds are 
comparatively similar to the agonist molecule (PIM2) in terms of negative value (affinity). However, the free 
binding energy, DSX value and toxic properties for XPX are better than its counterpart ligand molecules. 
Hence, we propose that predicted molecule (XPX) is a potential lead molecule as an antagonist of LprG 
protein. Further, in vitro biological assays for XPX is needed to be performed to establish its efficacy in 
preventing molecular evasion mechanism of MTB within host macrophages. This study shall contribute 
immensely to the development of a novel class of ligands against tuberculosis that will boost the 
pharmaceutical sector in processing the lead compound for clinical trials. 
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